31R.F Revive Therapeutics Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
0.0110 EUR
Close of Nov 11, 2026
0.0005 0.0555
Market cap
EUR 4.89M
P/E
-
P/B
0.12x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.

Is 31R.F undervalued?

Graham number

The Graham number of Revive Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Revive Therapeutics Ltd fundamental analysis

No fundamental analysis for Revive Therapeutics Ltd yet.

Revive Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develop…

Full company profile